# Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects

> **NCT05095168** · PHASE1 · COMPLETED · sponsor: **CARE Pharma Shanghai Ltd.** · enrollment: 31 (actual)

## Conditions studied

- PNH

## Interventions

- **DRUG:** CAN106
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05095168
- **Lead sponsor:** CARE Pharma Shanghai Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-22
- **Primary completion:** 2021-11-30
- **Final completion:** 2021-11-30
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05095168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05095168, "Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05095168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*